IMI (Inverness Medical Innovations) completes buy of Apogent's Applied Biotech:
This article was originally published in Clinica
Inverness Medical Innovations (IMI) has completed its acquisition of San Diego, California-based Applied Biotech, the rapid diagnostic test manufacturing subsidiary of Apogent Technologies. The deal releases Apogent from any further patent infringement claims by IMI relating to products sold by Apogent before the acquisition closed. Apogent decided to sell the unit because of its exposure to IMI's patent protection action in the fields of rapid pregnancy, drugs of abuse and infection testing (see Clinica No 1069, p 15).
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.